Compare TEVA & LII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEVA | LII |
|---|---|---|
| Founded | 1901 | 1895 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.2B | 17.4B |
| IPO Year | N/A | 1999 |
| Metric | TEVA | LII |
|---|---|---|
| Price | $28.38 | $511.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 12 |
| Target Price | $27.00 | ★ $605.18 |
| AVG Volume (30 Days) | ★ 11.4M | 451.7K |
| Earning Date | 11-05-2025 | 10-22-2025 |
| Dividend Yield | N/A | ★ 1.02% |
| EPS Growth | N/A | ★ 12.46 |
| EPS | 0.62 | ★ 23.67 |
| Revenue | ★ $16,776,000,000.00 | $5,345,300,000.00 |
| Revenue This Year | $4.74 | N/A |
| Revenue Next Year | $0.48 | $7.34 |
| P/E Ratio | $46.12 | ★ $21.62 |
| Revenue Growth | 0.02 | ★ 3.77 |
| 52 Week Low | $12.47 | $443.19 |
| 52 Week High | $28.68 | $689.44 |
| Indicator | TEVA | LII |
|---|---|---|
| Relative Strength Index (RSI) | 80.93 | 60.54 |
| Support Level | $24.01 | $481.60 |
| Resistance Level | $26.96 | $499.95 |
| Average True Range (ATR) | 0.68 | 14.23 |
| MACD | 0.19 | 6.58 |
| Stochastic Oscillator | 94.65 | 99.78 |
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2024, residential HVAC was 67% of sales and commercial HVAC and Heatcraft refrigeration was 33% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.